CompletedHealthcare23 January 2026

BioCryst Pharmaceuticals, Inc. to acquire Astria Therapeutics, Inc.

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
BioCryst Pharmaceuticals, Inc.
Target
Astria Therapeutics, Inc.
Deal value
Not disclosed
Announced
23 January 2026
Status
Completed
Sector
Healthcare
Country
United States
Consideration
shares, cash
What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update
  1. CompletedClosed

    BioCryst Pharmaceuticals, Inc. completes acquisition of Astria Therapeutics, Inc.

    Item 1.01. Entry Into a Material Definitive Agreement. On January 23, 2026 (the “ Closing Date ”), in connection with the Merger (as defined below) and immediately following the Effective Time (as defined below), Astria Therapeutics, Inc., a Delaware corporation (“ Astria ”), executed a joinder and thereby became a party to and guarantor under a Loan Agreement (the “ Loan Agreement ”) entered into

    Source

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

Similar deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

30 June 2026Firm intentionHealthcare

Public Company Management Corporation to acquire Physicians Capital Management Corporation

Public Company Management Corporation has agreed to acquire Physicians Capital Management Corporation in a strategic acquisition within the healthcare sector. The transa…

Buyer
Public Company Management Corporation
Target
Physicians Capital Management Corporation
Deal value
Not disclosed
Deal type
strategic acquisition

Buyer history

BioCryst Pharmaceuticals, Inc.

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive